U.S. Securities and Exchange Commission
Washington, D.C. 20549
Form 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2000
-------------
[ ] TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 0-18881
-------
BRADLEY PHARMACEUTICALS, INC.
-----------------------------
(Exact name of small business issuer as specified in its charter)
Delaware 22-2581418
-------- ----------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
383 Route 46 West, Fairfield, NJ
--------------------------------
(Address of principal executive offices)
(973) 882-1505
--------------
N/A
---
(Former name, former address and former fiscal year, if changed since last
report)
Check whether the issuer (1) filed all reports required to be filed by section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
Title of Each Class Number of Shares Outstanding
of Common Stock as of August 1, 2000
--------------------- ------------------------------
Common Stock, $.01 Par Value 8,206,289
Class B, $.01 Par Value 431,552
Transitional Small Business Disclosure Format (check one):
Yes No X
--- ---
BRADLEY PHARMACEUTICALS, INC.
INDEX TO FORM 10 - QSB
June 30, 2000
Page
Number
------
Part I - Financial Information
Financial Statements (unaudited):
Condensed Consolidated Balance Sheet -
June 30, 2000 3
Condensed Consolidated Statements of
Operations - three and six months ended June 30,
2000 and 1999 4
Condensed Consolidated Statements of Cash
Flows - six months ended June 30, 2000
and 1999 5
Condensed Notes to Consolidated Financial Statements 7
Management's Discussion and Analysis 11
Part II - Other Information
Item 1. Legal Proceedings 15
Item 5. Other Information 15
Item 6. Exhibits and Reports on Form 8-K 15
Signatures 16
2
